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Abstract 
Hypophysitis is a broad term used to describe conditions leading to inflammation of the pituitary gland and the pituitary stalk. It may 
develop as a primary condition or secondary to other diseases. Hypophysitis is classified based on aetiological, anatomical, and histological 
criteria. Clinical symptoms result from enlargement of the pituitary gland, hormonal deficiencies, diabetes insipidus, and hyperprolac-
tinemia. Histopathological verification of tissue samples from a pituitary biopsy remains the gold standard in diagnosing hypophysitis. 
However, due to the invasiveness and risk of the procedure it is rarely performed. The diagnosis is based mainly on clinical presentation, 
laboratory tests, and imaging. The rarity of the disease and the deficit in reliable data result in a lack of clear guidelines in the treatment of 
hypophysitis. The basic therapy relies on hormonal replacement. High doses of steroids are the first-line treatment of symptoms caused 
by mass effect in sella and compression of surrounding structures. In steroid-resistant patients or in cases of inacceptable sides effects, 
treatment with other immunosuppressant drugs was administered with success. The course of the disease varies: some patients pres-
ent remission, in other cases hypophysitis leads to fibrosis and atrophy of the pituitary gland, which is reflected in persistent hormonal 
deficiencies and images of an empty sella. The objective of this article is to present the most important information: the epidemiology, 
clinical image, diagnostic procedures, and treatment of primary hypophysitis, 
in order to allow better understanding of this disease and implementation of proper management. Posttraumatic and immunotherapy-
related hypophysitis are also briefly characterised. (Endokrynol Pol 2019; 70 (3): 260–269)
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Introduction 
Hypophysitis is a broad term used to describe conditions 
leading to inflammation of the pituitary gland and the 
pituitary stalk. Hypophysitis may develop as a primary 
condition or secondary to other causes such as systemic 
diseases, drugs, or pathologies located near the sella tur-
cica. Despite being a rare condition, progress in radiol-
ogy studies, enhanced understanding of endocrinology, 
and new variants (IgG4- and immunotherapy-related) 
being discovered, interest in this disease is increasing. 
The first scientific works concerning hypopituitarism 
caused by infective factors were published at the begin-
ning of the 20th century [1, 2], but research about the 
primary pituitary pathologies leading to its insufficiency 
started just under 50 years ago. 
Classification 
Hypophysitis may be classified based on aetiological, 
anatomical, and histological criteria. Aetiologically, we 
distinguish primary inflammation — limited to the 
pituitary gland — as one occurring without a trace-
able triggering factor. Secondary hypophysitis may 
be related to infectious (tuberculosis, syphilis) and 
systemic (sarcoidosis, Crohn’s disease, Langerhans cell 
histiocytosis) diseases, therapeutic drugs (interferon, 
interleukin-2, CTLA-4, and PD-1 inhibitors) or tumours 
in the area of sella turcica (pituitary adenomas, cranio-
pharyngiomas, germinomas). Different parts of the 
pituitary gland can be subject to the disease. Specifically, 
inflammation of the anterior pituitary lobe (lymphocytic 
adenohypophysitis), the posterior pituitary lobe and 
stalk (lymphocytic infundibuloneurohypophysitis) 
or the entire pituitary gland (lymphocytic panhy-
pophysitis) are characterised by a prevalence of 65, 10, 
and 25%, respectively [3, 4]. Histological classification 
includes lymphocytic, granulomatous, xanthomatous, 
IgG4-related (plasmacytic), and necrotising hypophy-
sitis [3]. Sporadically mixed variants have also been 
identified, but some authors regard them as diseases 
with different expressions [5].
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Plasmocytic or IgG4-related hypophysitis
Another type of hypophysitis is plasmocytic or 
IgG4-related hypophysitis. It may involve only the 
pituitary gland, but it may also manifest as a systemic 
disease, which explains why many authors consider 
this type as secondary. According to the majority of 
reports, older men are the most commonly affected 
patients, with a male-female ratio of 2:1. One research 
project showed higher prevalence among women 
[22]. The aetiology of this subtype is not clear, but 
autoimmune background and inappropriate reaction 
to unknown allergens or infectious factors are taken 
into consideration [23, 24]. In the course of systemic 
disease, many organs may be involved: lymph nodes, 
liver, pancreas, lungs, thyroid gland, and others [24, 
25, 26]; the pituitary gland is affected in 2-8% of cases 
[27]. Plasmocytic hypophysitis has been considered 
rare, but according to new research and retrospective 
analyses of previous doubtful cases, the prevalence 
is actually higher than expected [22, 28]. The criteria 
based on pituitary MRI, involvement of other organs, 
serum IGg4 level, and response to treatment allow 
a diagnosis to be established without a necessary pitu-
itary gland biopsy [29].
Necrotising inflammation
The rarest type of hypophysitis is a necrotising 
inflammation of the pituitary gland, which was 
diagnosed in four patients at the ages of 12, 20, 
33, and 39 years (three cases were confirmed by 
a biopsy). This subtype was predominantly seen in 
men [30]. 
Risk factors
Pregnancy and childbirth are considered risk factors for 
primary hypophysitis [31]. According to Suzuki et al., 
an additional factor increasing the risk of lymphocytic 
adenohypophysitis is aseptic meningitis [32]. 
Lymphocytic hypophysitis and pregnancy
As mentioned previously, lymphocytic hypophysitis 
(mainly adenohypophysitis) is strongly correlated with 
pregnancy and the puerperal period. The occurrence 
of the disease does not have any adverse influence on 
the foetus or the course of pregnancy [3, 33, 34]. Previ-
ous pregnancies do not increase the risk of developing 
hypophysitis in subsequent pregnancies; a woman is 
able to become pregnant with pre-existing pituitary 
inflammation [33, 35, 36]. In pregnancy, the pituitary 
gland volume increases by about 30% [37], mostly due 
to hyperplasia and hypertrophy of the lactotrophs [38], 
which may facilitate the release of pituitary antigens 
Epidemiology
Hypophysitis is a rare disease. The original annual 
incidence estimated at approximately one case per 
9 million [6] seems to be an underestimation, at least 
due to increasing diagnosis of IgG4-related pituitary 
inflammation [3]. Hypophysitis is considered to cause 
approximately 0.4% (0.24–0.88%) of the neurosurgical 
interventions within the pituitary gland [3, 7]. The 
condition is accompanied in 8–20% of cases by other 
autoimmune diseases, amongst which Hashimoto’s 
and Graves-Basedow thyroiditis are the most common 
[3, 8–10]. Hypophysitis may be a part of autoimmune 
polyglandular syndrome, in particular type 3A, but 
also type 1 [11, 12]. People with HLA DR4, HLA DR5, 
HLA DQ8, and HLA DR53 alleles are thought to have 
a predisposition to be affected by primary hypophy-
sitis [13, 14].
Lymphocytic inflammation
Lymphocytic inflammation is the most common his-
tological variant of hypophysitis — 68% of cases [4]. It 
was described for the first time in 1962 by Goudi and 
Pinkerton [15]; women are more frequently affected, 
with a 3:1 ratio [3], typically in the fourth decade of 
life. Lymphocytic hypophysitis shows strong asso-
ciation with pregnancy (in contrast to other primary 
inflammations of the pituitary gland). In the major-
ity of women, it was diagnosed in the last month of 
pregnancy or in puerperal period, predominantly 
within two months of delivery [3, 16]. The aetiology 
is probably autoimmune. 
Granulomatous inflammation
The second most common variant of hypophysitis 
is granulomatous inflammation, representing about 
20% of diagnosed cases [4]. The first posthumous 
case was presented by Simmonds in 1917, and 
the first antemortem description was seen in 1980 
[17, 18]. The aetiology is unknown. Granuloma-
tous inflammation affects women more often than 
men (3:1 ratio), mainly in the fifth decade of life. 
It is necessary to exclude other diseases associated with 
granulomas (tuberculosis, sarcoidosis, histiocytosis) 
prior to considering granulomatous pituitary gland 
inflammation as primary [19].
Xanthomatous inflammation
A rare type of hypophysitis is xanthomatous inflam-
mation (about 3% of cases [4]), discovered in 1998. It 
is believed that this variant may be an inflammatory 
reaction to Ratke’s cleft cyst rupture [20, 21].  It has 
been more frequently reported in women (3:1), in their 
fourth decade of life. 
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[39]. Moreover, due to the significant increase in oes-
trogen concentration, the pituitary vascularity changes 
and favours blood supply from the systemic circulation 
[40]. These modifications and the increase in tissue size 
explain why the immune system has a greater ability 
to target the pituitary gland during pregnancy. One 
of the factors that may connect pregnancy with hy-
pophysitis is alpha-enolase, which was documented to 
be expressed in both the pituitary gland and placenta 
[41]. However, antibodies against this enzyme are not 
specific for lymphocytic inflammation because they are 
also present in other pituitary diseases [42]. Tumour 
necrosis factor (TNF) alpha is mentioned amongst po-
tential causes of hypophysitis — its action is blocked 
by placenta-derived soluble TNF receptor 1 protein 
[43]. In contrast, a recent German retrospective analysis 
of  66 patients documented the relationship between 
pregnancy and hypophysitis (all variants) in only 11% 
of cases [44]. This difference may suggest the contribu-
tion of environmental factors in the pathogenesis of 
primary pituitary inflammations [45].   
Symptoms
The clinical image of lymphocytic hypophysitis varies 
— both in the case of the disease onset, which may be 
acute or latent, as well as its course [46]. In some pa-
tients, the inflammation develops rapidly, in others — in 
an insidious way [47, 48]. The time between the first 
symptoms and diagnosis is markedly longer for adeno-
hypophysitis outside of pregnancy (median 12 months) 
than during pregnancy (median four months) and in 
comparison with infundibuloneurohypophysitis (me-
dian three months) and panhypophysitis (median four 
months) [3]. Furthermore, based on pathologies found 
in posthumous examination in patients without symp-
toms during their life, we may suspect an asymptomatic 
course of the disease in some cases [13, 49]. 
Clinical symptoms may be classified in four catego-
ries: connected with enlargement of pituitary gland, 
hormonal deficiencies, diabetes insipidus, and hyper-
prolactinaemia. 
Headaches and visual disturbances are the first 
and most common manifestations of hypophysi-
tis. Headaches with concomitant nausea and vomiting 
are thought to be an effect of pituitary size increase, 
which causes deformation of the dura mater and the 
diaphragma sellae. Levy et al. proved in their work 
that there is no correlation between the pituitary gland 
volume and the severity, frequency, or duration of 
headaches, which suggests that there are additional 
causes of symptoms apart from mass effect [50]. Visual 
disturbances, including defects in vision field, dete-
rioration in acuity of vision, and colour perception, 
arise from the compression of optic chiasm. Diplopia 
is rarely reported — only in patients with expansion 
of the enlarged pituitary gland into cavernous sinuses 
and those with compression of the oculomotor nerves 
[51–54]. Weight gain was observed in 18% of patients 
in a German study [44]. An unusual complication of 
hypophysitis is internal carotid artery occlusion [55]. 
Cases of pituitary apoplexy in the course of hypophy-
sitis accompanied by severe neurological symptoms 
have also been reported [56, 57]. 
Deficit in the hormones of the anterior pituitary 
lobe may be a consequence of inflammatory infiltration 
or compression of the pituitary gland or/and hypo-
thalamus [46, 58]. Contrary to other causes of pituitary 
insufficiency, hypophysitis is characterised by frequent 
disturbances in ACTH and TSH secretion, which is 
associated with a risk of life-threatening adrenal crisis 
[4]. Recent research underlines a common presentation 
of gonadotropin deficiency [44, 59]. Decreased growth 
hormone production is the rarest abnormality. The 
possibility of a single pituitary hormone deficiency is 
a typical feature of hypophysitis — most often it ap-
plies to ACTH [48, 60]. Secondary adrenal insufficiency 
may have a particularly severe course in cases of a con-
comitant deficiency in vasopressin (ADH) because, in 
physiological conditions, ADH expresses a synergistic 
effect with CRH on ACTH release [13]. In rare situations, 
a severe and rapid case of adrenal cortex insufficiency 
may lead to sudden death [3, 13, 31, 58]. Because there 
is usually no correlation between radiological imaging 
and the degree of hormonal deficits [61, 62], one can 
conclude that  autoimmune processes affect pituitary 
secreting cells and lead to subsequent endocrine dis-
turbances [63, 64]. 
In hypophysitis, the prolactin level may be normal, 
increased, or decreased [13, 16]. Hyperprolactinaemia 
has a multifactorial background — compression of 
a pituitary stalk, modification of dopamine receptor ac-
tivity, lactotroph hypertrophy, and infiltration of secre-
tory cells with lymphocytes, which lead to subsequent 
damage and release of prolactin into the circulation. 
There is also a hypothetical possibility of the presence 
of antibodies stimulating production and secretion of 
prolactin [3, 13]. Hyperprolactinaemia causes menstrual 
irregularities, galactorrhoea, decreased libido [65, 66], 
and osteoporosis in the long run [67]. Persistent elevated 
prolactin level may favour protraction of hypophysitis 
due to its proinflammatory effect [68].
Diabetes insipidus (DI) occurs in approximately 
35% of patients with lymphocytic hypophysitis 
[4]. It results from the compression of the pos-
terior pituitary lobe and/or the stalk or due to 
a direct autoimmune reaction. DI may be present also 
in adenohypophysitis, which is explained by inhibi-
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tion of axonal anti-diuretic hormone transport caused 
by swollen pars tuberalis [69]. The concomitant deficit 
in glucocorticoids, which normally inhibit the secre-
tion of vasopressin and aquaporin-2, masksing the DI 
symptoms [69–71]. 
Granulomatous hypophysitis is characterised by 
more severe symptoms. Hunn et al. determined the 
prevalence of headaches, visual disturbances, poly-
dipsia/polyuria, and cranial nerve palsies in 61, 40, 27, 
and 27% of cases, respectively; panhypopituitarism was 
diagnosed in 49% and DI in 27% of cases [19]. A few 
sources have reported relatively frequent occurrence of 
nausea, vomiting, and meningeal signs [58].
Due to the low prevalence of xanthomatous and 
plasmocytic, hypophysitis data about the course of these 
variants is scarce. Based on described cases, Gutenberg et 
al. stated that xanthomatous hypophysitis did not cause 
optic chiasm compression, and it is associated with lower 
risk of DI as well as fewer hormonal disturbances (GH 
and FSH/LH deficits more frequent than ACTH and TSH 
deficiencies) [72]. IgG4-related pituitary inflammation 
involves the pituitary gland and the stalk in 65% of cases, 
causing panhypopituitarism in 50%, anterior pituitary 
lobe dysfunction in 25%, and DI in 18% of cases [73]. 
Primary hypophysitis in children 
Primary hypophysitis occurs rarely in children and is 
characterised by a different course. The most common 
manifestation is DI — present in 85% of cases. The 
prevalence of growth hormone deficit was estimated 
in 76% of cases, but deficiencies of gonadotropins, TSH, 
and ACTH are rarer [74]. Headaches and problems with 
sight are present in 17% and 8%, respectively. Due to 
the similarity of symptoms (DI and growth inhibi-
tion) tumours like germinoma, craniopharyngioma, 
or Langerhans cell histiocytosis should be taken into 
consideration in the differential diagnosis [75]. Chil-
dren with suspicion of hypophysitis have a greater 
risk of germinoma and require careful monitoring [74, 
75]. Germinomas may be also the cause of secondary 
pituitary gland inflammation. 
Diagnostics
Histopathological verification of tissue samples from 
a pituitary biopsy remains the gold standard in diagnos-
ing hypophysitis. However, due to the invasiveness and 
risk of the procedure, it is rarely performed. Histological 
aspects of primary pituitary inflammations were widely 
described in numerous works [3, 4, 19, 29, 47, 76–78] 
and are not discussed in this article. The diagnosis is 
based mainly on clinical presentation, laboratory tests, 
and imaging. 
Laboratory tests
Full hormonal assessment with measurements of 
ACTH, morning cortisol, GH, IGF-1, oestradiol (in pre-
menopausal women), testosterone (in men), LH, FSH, 
TSH, fT4, PRL, urine/plasma osmolality, sodium, and 
potassium concentration should be performed. At the 
time of diagnosis of lymphocytic hypophysitis, ACTH 
deficit was found in 60% of cases, FSH/LH in 55%, TSH 
in 52%, ADH in 39%, GH in 38%, hyperprolactinaemia 
in 37%, and hyperprolactinaemia in 26% of cases [4]. 
Abnormalities in basic tests such as total blood count, 
inflammatory markers, and kidney and liver function 
parameters are an element of differential diagnostics, 
which is required to exclude a secondary cause of the 
disease [54]. 
Imaging
Despite significant progress in radiology, recognition 
of hypophysitis is still challenging. Magnetic resonance 
with administration of gadolinium contrast remains 
the gold standard of imaging. The features suggesting 
primary hypophysitis are a homogeneously enhanced 
pituitary gland, thickening of a non-deviated stalk (in 
86% cases [44]), absence of signal from the posterior 
pituitary lobe (more common in patients with DI), and 
a dural tail sign [79]. It is important to notice that the 
posterior pituitary lobe signal is also absent in 20% of 
healthy people, especially in the older population [4], 
and the dural tail sign is not specific because it may oc-
cur in meningiomas (the most common relation) and in 
other intracranial pathologies [80]. Bone structures of 
sella turcica generally remain intact [3, 9]. The changes 
mentioned above are expressed mostly in lymphocytic 
hypophysitis and may not be present in the other vari-
ants of the disease. Turcu et al. assessed a pattern of 
pituitary stalk lesion enhancement in MRI. They found 
the strongest connection between round/diamond pat-
tern and congenital lesions. Unfortunately, apart from 
patients with xanthoma disseminatium (a pyramidal 
pattern of enhancement), no associations between 
characteristic MRI image and other inflammatory le-
sions were detected [81].
In granulomatous hypophysitis, the distention of 
the sellar area is frequently observed, which makes 
it more challenging to differentiation from tumours 
[58]. It should be underlined that an empty sella image 
may result from a long-lasting hypophysis, leading 
to atrophy [47, 82]. The distinction between pituitary 
adenoma and hypophysitis is often difficult. To facili-
tate the differentiation between these two conditions, 
Gutenberg et al. established a scale including time 
relation to pregnancy, volume and symmetry of the pi-
tuitary mass, signal intensity, signal homogeneity after 
contrast administration, presence of posterior pituitary 
264
Hypophysitis — new insights into diagnosis and treatment Łukasz Kluczyński et al.
R
E
V
IE
W
bright spot, stalk size, and mucosal swelling. The result 
is measured between –13 and +8 points. A score higher 
than 0 suggests adenoma, and equal to or lower than 0 
suggests hypophysitis [83].    
Patients with a suspicion of hypophysitis should 
have their vision field and acuity of vision checked. 
Immunology
Due to the suspicion of autoimmune character of at 
least part of hypophysitis, many works were devoted 
to identifying the antigen/antigens responsible for the 
disease. Many different molecules like alpha-enolase 
[84], secretogranin II [85], PGSF1a, and PGSF2 [86] 
were proposed, but their role in the pathogenesis of the 
disease was not clearly proven. Allix et al. revealed the 
presence of antibodies against rabphilin-3A in 76% of 
patients with lymphocytic infundibuloneurohypophy-
sitis. The antibodies are not detected in other parasellar 
pathologies, which may indicate that they can be used 
as disease biomarkers in the future [87, 88].  The choice 
of the best method of assessing anti-pituitary antibodies 
remains controversial; however, currently the indirect 
immunofluorescence is thought to be the most reliable 
[31, 89]. Nonetheless, due to the low antibody sensitiv-
ity — reaching 36% in lymphocytic adenohypophysitis 
[3] — and the presence of anti-pituitary antibodies 
in other autoimmune diseases (Hashimoto’s disease, 
diabetes type 1), which reduces their specificity, these 
antibodies cannot be considered as a fully useful diag-
nostic tool. That being said, lack of antibodies against 
the pituitary gland does not allow for exclusion of the 
hypophysitis, because they may be present at the begin-
ning of the disease and then disappear [8]. De Bellis et 
al. detected the presence of immunoglobulins against 
CRH-producing cells in patients with a deficit in ACTH 
and TSH and anti-pituitary antibodies against GH, in-
dicating potential autoimmune reaction involving the 
hypothalamus [90]. Assessment of antibodies against 
anti-diuretic hormone in patients with hypophysitis 
may be helpful in identifying cases with a greater risk 
of developing DI [91]. 
Differential diagnosis
Hypophysitis should be primarily differentiated from 
a pituitary adenomas and Sheehan syndrome (post-
partum pituitary gland necrosis). In prolactinomas, 
which often enlarge during pregnancy, a history of 
menstrual disturbances and difficulty in getting preg-
nant [65, 66] is frequent. However, such abnormalities 
are rarely reported in hypophysitis [61]. In the case of 
uncertainty, magnetic resonance can be useful because 
in hypophysitis, stalk deviation, and destruction of sella 
bone structures are not observed, while adenomas may 
cause infundibulum displacement and erosive changes 
in the sellar floor [3, 92]. Postgadolinium enhancement 
in hypophysitis is predominantly homogenous, more 
intensive, and seen earlier than in adenomas, with 
a positive dural tail sign; lack of posterior pituitary 
lobe signal is common [3]. Finally, the pattern of hor-
monal deficits is different in adenomas, one can detect 
deficiencies of GH, then LF/FSH, and subsequently 
TSH and ACTH, but in hypophysitis adrenal axis 
insufficiency is the earliest finding, followed by abnor-
malities of the thyroid and gonadal axes; the GH level 
is decreased less often [4]. Some authors suggest that 
a test with dopamine agonists be performed in the case 
of doubt in differentiation between hypophysitis and 
prolactinoma — in the latter, a reduction of tumour 
size is usually detected, an effect that is not observed 
in inflammation of the pituitary gland, despite the 
decrease in prolactin concentration [24]. The common 
characteristic of hypophysitis and Sheehan syndrome is 
that they are often seen in the puerperal period [61, 93]. 
The first symptoms of hypophysitis are preponderantly 
present in late pregnancy, while Sheehan syndrome is 
associated with consequences of traumatic course of 
childbirth with haemodynamic complications. The clas-
sic presentation of postpartum necrosis of the pituitary 
gland is absent lactation, which is quite uncommon 
in lymphocytic pituitary inflammation [93]. In both 
conditions, the development of symptoms of empty 
sella syndrome with multiple hormonal deficiencies 
may occur in the long run [61, 93]. Distinction between 
postpartum pituitary gland necrosis and hypophysitis 
is not always possible — ischaemia in the course of 
Sheehan syndrome may elicit an autoimmune reaction 
leading to persistent hypopituitarism [94].
Treatment
The rarity of the disease and the deficit in reliable data 
result in a lack of clear guidelines in the treatment of 
hypophysitis. The basic therapy relies on hormonal 
replacement [95, 96] in accordance with standard treat-
ment of hypopituitarism and DI. Administration of ad-
renal hormone substitution should precede implemen-
tation of levothyroxine. Inhibiting pituitary hormone 
production with a subsequent reduction in hypothetical 
pituitary antigen expression after treatment initiation 
may stop or impede the progression of the disease [8]. 
If the symptoms are not severe and are not increasing, 
further careful observation is possible [44, 97]. This does 
not apply to IgG-4-related hypophysitis — in which 
case steroids are advised in order to reduce symptoms 
and prevent fibrosis [98]. The starting dose is 30–40 mg 
of prednisone or equivalent, with subsequent reduction 
[26]. Some patients benefit from long-term therapy. Due 
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to the possibility of recurrences, some cases require re-
peated cycles of steroids [4]. Treatment with rituximab 
or azathioprine may be used in patients with poor 
response to glucocorticoids [26, 99]. High doses of ste-
roids are the first-line treatment in symptoms caused by 
mass effect in the sella and compression of surrounding 
structures. In steroid-resistant patients or in the case of 
inacceptable sides effects, treatment with azathioprine, 
methotrexate, rituximab, and cyclosporine A was ad-
ministered with success [45, 100]. However, long-term 
observation of patients on these therapies is still absent. 
Due to reports about immunomodulatory prolactin 
action, some authors advocate the use of dopamine 
agonists in order to initiate the response for treatment 
[68, 101], but the efficacy of this method is uncertain 
[45]. Bromocriptine or cabergoline may help to reduce 
symptoms resulting from hyperprolactinaemia and 
decrease vision field deficits [58].  
Surgical treatment — the historical treatment of 
choice [3] — is currently reserved for patients with se-
vere deficits in their vision fields, impaired vision acuity, 
and oculomotor nerve palsies, as well as those who are 
resistant to pharmacological treatment. The advantage 
of invasive methods is the possibility of histopathologi-
cal assessment of material taken during surgery, which 
allows a final diagnosis to be made. However, the draw-
backs include the risk of complications: deterioration in 
vision, development of diabetes insipidus, worsening of 
pituitary dysfunction [48, 57], bleeding, or even causing 
cerebrospinal fluid leakage [3]. 
Radiotherapy is an option for patients in whom 
other methods appeared to be unsuccessful or those 
with recurrent disease. 
Prognosis
Little is known about the natural history of hypophysitis, 
and the majority of the information concerns the lym-
phocytic variant. Prognostic factors include the degree 
of pituitary infiltration, severity of fibrosis, presence 
of symptoms resulting from compression, and steroid 
susceptibility [102]. The disease may have a self-limiting 
course [44, 47, 97]. According to a recent German study, 
MRI changes in patients without any active treatment 
revealed improvement, stabilisation, or deterioration 
in pituitary involvement in 46, 27, and 27% of cases, re-
spectively. Hormonal function improved in 27% and re-
mained unchanged in 55%; 18% of patients experienced 
progression [44]. Previously, Khare et al. documented 
spontaneous resolution of sella turcica compression in 
all observed patients, with at least partial improvement 
in pituitary function in 33% of them [97].  
In patients qualified for therapy with high-dose 
steroids, the improvement of hormonal function was 
observed only in 15% of cases; in 70% it remained 
stable, while 15% of patients presented progression. 
Good response with radiological improvement, stabi-
lisation, or deterioration was found in 65, 31, and 4% 
of cases, respectively [44]. More than 70% of patients 
required long-term substitution with one or more 
anterior pituitary hormones [3]. Diabetes insipidus is 
usually persistent. The risk of relapse is estimated at 
about 38%, independently of initial drug dose and dura-
tion of the therapy [44]. Recurrence occurs commonly 
within 2–17 months from the beginning of treatment. 
A literature review made by Lupi et al. presented more 
optimistic results: reduction in pituitary size in 88% of 
cases, improvement in anterior and posterior pituitary 
lobe function in 45% and 41%, respectively, with low 
risk of relapse — 14% [103]. The occurrence of diabetes 
insipidus is an unfavourable factor in the context of 
response to glucocorticoids [104]. Lack of sensitivity 
to steroids and frequent, severe side-effects limit this 
method of treatment. 
Steroid therapy brings much worse effects in the 
treatment of granulomatous and xanthomatous hy-
pophysitis [72].
Surgical treatment leads to significant improvement 
in headaches and visual disturbances [44, 72]. Relapses 
are described in 11–25% of cases [44]. Postoperative 
observations show a large number of patients with 
pituitary insufficiency [54].
In its course, hypophysitis frequently leads to fibro-
sis and atrophy of the pituitary gland, which is reflected 
in hormonal deficiencies and images of an empty sella. 
Hypophysitis-related mortality was estimated to 
be about 7% of cases, which is probably an effect of 
unrecognised adrenal cortex insufficiency [4]. 
Immunotherapy-related hypophysitis
Checkpoint inhibitors are monoclonal antibodies 
used in oncological therapies; their role is to inhibit 
the regulators of autoimmune responses [4]. Hy-
pophysitis may be one of their side-effects, and it is 
seen in 0–17% of patients treated with anti-CTLA-4 
antibody [105, 106] and in less than 1% of patients 
treated with anti-PD1 or anti-PD-L1 antibodies 
[107]. The symptoms appear most frequently after 
2–3 months of therapy (on average — nine weeks) 
[108]. Male sex (4:1 ratio) and older age (average age 
of diagnosis — 59 years) are reported among the 
most common risk factors [4, 89, 109]. The potential 
mechanism of inflammation is based on type II and 
IV hypersensitivity and on humoral response, with 
the production of anti-pituitary antibodies targeted 
mainly TSH, FSH, and ACTH-secreting cells [4, 
110–112]. Patients present with headaches and symp-
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toms resulting from anterior pituitary lobe hormone 
deficiencies, which are seen in over 70% of cases; the 
adrenal, thyroid, and gonadal axes are affected in 
about 91, 84, and 83% of patients, respectively [100]. 
A decrease in TSH concentration may be an early 
sign of developing hypophysitis [113]. Reliable data 
about somatotrophic axis dysfunction is missing. In 
sporadic cases, hyponatraemia was also observed 
[114]. Diabetes insipidus is extremely rare, which dis-
tinguishes immunotherapy-related hypophysitis from 
other forms of pituitary inflammations [105, 115]. Up 
to 45% of patients may be asymptomatic but present 
with abnormal laboratory findings [116]. Normal size 
or moderate enlargement of the pituitary gland (in 
about 50% of patients it precedes the occurrence of 
clinical symptoms [109]), usually without optic chiasm 
compression, is observed in imaging. The diagnosis 
is based on clinical presentation, results of laboratory 
tests, and imaging as well as short period of time 
elapsing from the exposure to immunotherapy [109, 
115]. Pituitary hormone substitution and steroids in 
high doses are used in therapy. The decision about 
continuation or cessation (transient or persistent) of 
immunotherapy should be based on the degree of 
severity of symptoms and requires close cooperation 
of an oncologist and endocrinologist. Normalisation 
in the radiological image is most likely to be observed 
within two months [115]. Restoration of function of 
gonadal and thyroid axes is obtained quite commonly; 
the adrenal axis usually requires long-term substitu-
tion [89, 116, 117]. An additional issue is the ability to 
differentiate between immunotherapy-related hy-
pophysitis and metastasis to the pituitary gland [109, 
117]. An important distinguishing factor is diabetes 
insipidus, rarely seen in checkpoint-inhibitor related 
hypophysitis but common (in about 45%) in the case 
of a mass in the pituitary gland [4]. 
Traumatic brain injury
Traumatic brain injury (TBI) may lead to permanent 
or transient pituitary insufficiency. The pathophysi-
ology of the hypopituitarism after TBI is not fully 
understood. Apart from the direct effects of trauma 
and vascular damage, an interaction between the TBI 
and autoimmunity has been indicated. Anti-pituitary 
and anti-hypothalamic antibodies could be present 
in patients with pituitary disorders related to TBI 
even five years after diagnosis [118]. In a prospective 
five-year observation of patients post TBI, those with 
higher titres of pituitary antibodies developed pituitary 
insufficiency more frequently, while the recovery of 
pituitary function was related to the negative antibody 
titres [119, 120]. 
Conclusions
Despite the increasing rate of detection, the diagnosis 
and management of hypophysitis remains challenging. 
Difficulties in establishing the exact diagnosis might also 
be related to the non-specific, transient characteristics of 
the symptoms and hormonal insufficiencies.  Long-term 
observations might help us better understand the dis-
ease. Further research is required in order to elaborate 
treatment algorithms and discover new disease bio-
markers that could help establish an accurate diagnosis 
without the need to perform a biopsy. 
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